Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Research Advances of Clinical Application of Oncolytic Viruses in Treatment of Gynecologic Cancers

Author(s): Mingjing Deng and Qi Wang*

Volume 23, Issue 7, 2023

Published on: 27 March, 2023

Page: [505 - 523] Pages: 19

DOI: 10.2174/1568009623666230221154415

Price: $65

conference banner
Abstract

Oncolytic viruses (OVs) have become one of the main strategies of cancer biotherapy. They are genetically engineered or naturally occurring viruses that selectively replicate and kill tumor cells without harming normal tissues. Gynecologic cancers have become a major health problem for women. OVs therapy plays an increasingly important role in the treatment of gynecological tumors with promising clinical effects. A variety of OVs is used in the treatment of gynecological tumors, either as single oncolytic virus therapy or in combination with other therapies. Some oncolytic virus therapies have entered early clinical trials and have shown favorable safety, clinical activity, and immune activation. The present study summarized the anti-tumor mechanism of OVs and their modifications. The study reviewed the latest clinical progress on the application of the OVs in the treatment of gynecologic cancers. The unique challenges in the development of the viruses as a novel drug for the treatment of gynecologic oncology were also discussed and their future prospects were elucidated.

Next »
Graphical Abstract

[1]
Russell, S.J.; Peng, K.W.; Bell, J.C. Oncolytic virotherapy. Nat. Biotechnol., 2012, 30(7), 658-670.
[http://dx.doi.org/10.1038/nbt.2287] [PMID: 22781695]
[2]
Hemminki, O.; Hemminki, A. A century of oncolysis evolves into oncolytic immunotherapy. OncoImmunology, 2016, 5(2), e1074377.
[http://dx.doi.org/10.1080/2162402X.2015.1074377] [PMID: 27057442]
[3]
Gong, J.; Sachdev, E.; Mita, A.C.; Mita, M.M. Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. World J. Methodol., 2016, 6(1), 25-42.
[http://dx.doi.org/10.5662/wjm.v6.i1.25] [PMID: 27019795]
[4]
Cuoco, J.A.; Rogers, C.M.; Mittal, S. The oncolytic newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma. Neurosurg. Focus, 2021, 50(2), E8.
[http://dx.doi.org/10.3171/2020.11.FOCUS20842] [PMID: 33524945]
[5]
Liu, H.; Luo, H. Development of group b coxsackievirus as an oncolytic virus: opportunities and challenges. Viruses, 2021, 13(6), 1082.
[http://dx.doi.org/10.3390/v13061082] [PMID: 34198859]
[6]
Engeland, C.E.; Ungerechts, G. Measles virus as an oncolytic immunotherapy. Cancers, 2021, 13(3), 544.
[http://dx.doi.org/10.3390/cancers13030544] [PMID: 33535479]
[7]
Ma, W.; He, H.; Wang, H. Oncolytic herpes simplex virus and immunotherapy. BMC Immunol., 2018, 19(1), 40.
[http://dx.doi.org/10.1186/s12865-018-0281-9] [PMID: 30563466]
[8]
Liu, W.; Wang, X.; Feng, X.; Yu, J.; Liu, X.; Jia, X.; Zhang, H.; Wu, H.; Wang, C.; Wu, J.; Yu, B.; Yu, X. Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models. Cancer Lett., 2022, 535, 215661.
[http://dx.doi.org/10.1016/j.canlet.2022.215661] [PMID: 35325845]
[9]
Shi, Z.; Liu, B.; Huang, C.; Xie, W.; Cen, Y.; Chen, L.; Liang, M. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy. Biochem. Biophys. Res. Commun., 2021, 559, 176-182.
[http://dx.doi.org/10.1016/j.bbrc.2021.04.078] [PMID: 33945995]
[10]
Kaufman, H.L.; Kohlhapp, F.J.; Zloza, A. Oncolytic viruses: A new class of immunotherapy drugs. Nat. Rev. Drug Discov., 2015, 14(9), 642-662.
[http://dx.doi.org/10.1038/nrd4663] [PMID: 26323545]
[11]
Zeng, H.; Zheng, R.; Guo, Y.; Zhang, S.; Zou, X.; Wang, N.; Zhang, L.; Tang, J.; Chen, J.; Wei, K.; Huang, S.; Wang, J.; Yu, L.; Zhao, D.; Song, G.; Chen, J.; Shen, Y.; Yang, X.; Gu, X.; Jin, F.; Li, Q.; Li, Y.; Ge, H.; Zhu, F.; Dong, J.; Guo, G.; Wu, M.; Du, L.; Sun, X.; He, Y.; Coleman, M.P.; Baade, P.; Chen, W.; Yu, X.Q. Cancer survival in China, 2003-2005: A population-based study. Int. J. Cancer, 2015, 136(8), 1921-1930.
[http://dx.doi.org/10.1002/ijc.29227] [PMID: 25242378]
[12]
Liontos, M.; Kyriazoglou, A.; Dimitriadis, I.; Dimopoulos, M.A.; Bamias, A. Systemic therapy in cervical cancer: 30 years in review. Crit. Rev. Oncol. Hematol., 2019, 137, 9-17.
[http://dx.doi.org/10.1016/j.critrevonc.2019.02.009] [PMID: 31014518]
[13]
Kuroki, L.; Guntupalli, S.R. Treatment of epithelial ovarian cancer. BMJ, 2020, 371, m3773.
[http://dx.doi.org/10.1136/bmj.m3773] [PMID: 33168565]
[14]
Santos, A.J. Lima de, S.G.V.; Cordeiro, S.M.L.; Silva Luz, M.; Silva, S.J.V.; Rocha, P.S.L.; de Souza, W.R.; Sande, L.M.; de Melo, F.F. Oncolytic virus therapy in cancer: A current review. World J. Virol., 2021, 10(5), 229-255.
[http://dx.doi.org/10.5501/wjv.v10.i5.229] [PMID: 34631474]
[15]
Thorne, S.H.; Hermiston, T.; Kirn, D. Oncolytic virotherapy: Approaches to tumor targeting and enhancing antitumor effects. Semin. Oncol., 2005, 32(6), 537-548.
[http://dx.doi.org/10.1053/j.seminoncol.2005.09.007] [PMID: 16338419]
[16]
Duan, Y.; Bai, H.; Li, X.; Wang, D.; Wang, Y.; Cao, M.; Zhang, N.; Chen, H.; Wang, Y. Oncolytic adenovirus H101 synergizes with radiation in cervical cancer cells. Curr. Cancer Drug Targets, 2021, 21(7), 619-630.
[http://dx.doi.org/10.2174/1568009621666210308103541] [PMID: 33687882]
[17]
Tian, L.; Xu, B.; Teng, K.Y.; Song, M.; Zhu, Z.; Chen, Y.; Wang, J.; Zhang, J.; Feng, M.; Kaur, B.; Rodriguez, L.; Caligiuri, M.A.; Yu, J. Targeting fc receptor-mediated effects and the “don’t eat me” signal with an oncolytic virus expressing an anti-cd47 antibody to treat metastatic ovarian cancer. Clin. Cancer Res., 2022, 28(1), 201-214.
[http://dx.doi.org/10.1158/1078-0432.CCR-21-1248] [PMID: 34645647]
[18]
Lin, Y.; Wang, W.; Wan, J.; Yang, Y.; Fu, W.; Pan, D.; Cai, L.; Cheng, T.; Huang, X.; Wang, Y. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines. Virol. J., 2018, 15(1), 65.
[http://dx.doi.org/10.1186/s12985-018-0975-x] [PMID: 29631630]
[19]
Ranki, T.; Joensuu, T.; Jäger, E.; Karbach, J.; Wahle, C.; Kairemo, K.; Alanko, T.; Partanen, K.; Turkki, R.; Linder, N.; Lundin, J.; Ristimäki, A.; Kankainen, M.; Hemminki, A.; Backman, C.; Dienel, K.; von Euler, M.; Haavisto, E.; Hakonen, T.; Juhila, J.; Jaderberg, M.; Priha, P.; Vassilev, L.; Vuolanto, A.; Pesonen, S. Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 + T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization. OncoImmunology, 2014, 3(10), e958937.
[http://dx.doi.org/10.4161/21624011.2014.958937] [PMID: 25941579]
[20]
Di Paolo, N.C.; Miao, E.A.; Iwakura, Y.; Murali-Krishna, K.; Aderem, A.; Flavell, R.A.; Papayannopoulou, T.; Shayakhmetov, D.M. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity, 2009, 31(1), 110-121.
[http://dx.doi.org/10.1016/j.immuni.2009.04.015] [PMID: 19576795]
[21]
Prestwich, R.J.; Errington, F.; Diaz, R.M.; Pandha, H.S.; Harrington, K.J.; Melcher, A.A.; Vile, R.G. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum. Gene Ther., 2009, 20(10), 1119-1132.
[http://dx.doi.org/10.1089/hum.2009.135] [PMID: 19630549]
[22]
Galon, J.; Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov., 2019, 18(3), 197-218.
[http://dx.doi.org/10.1038/s41573-018-0007-y] [PMID: 30610226]
[23]
Gholami, S.; Marano, A.; Chen, N.G.; Aguilar, R.J.; Frentzen, A.; Chen, C.H.; Lou, E.; Fujisawa, S.; Eveno, C.; Belin, L.; Zanzonico, P.; Szalay, A.; Fong, Y. Erratum to: A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. Breast Cancer Res. Treat., 2016, 156(3), 607-608.
[http://dx.doi.org/10.1007/s10549-016-3767-2] [PMID: 27026359]
[24]
Liu, B.L.; Robinson, M.; Han, Z-Q.; Branston, R.H.; English, C.; Reay, P.; McGrath, Y.; Thomas, S.K.; Thornton, M.; Bullock, P.; Love, C.A.; Coffin, R.S. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther., 2003, 10(4), 292-303.
[http://dx.doi.org/10.1038/sj.gt.3301885] [PMID: 12595888]
[25]
Puhlmann, M.; Brown, C.K.; Gnant, M.; Huang, J.; Libutti, S.K.; Alexander, H.R.; Bartlett, D.L. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther., 2000, 7(1), 66-73.
[http://dx.doi.org/10.1038/sj.cgt.7700075] [PMID: 10678358]
[26]
Smith, G.L.; Moss, B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene, 1983, 25(1), 21-28.
[http://dx.doi.org/10.1016/0378-1119(83)90163-4] [PMID: 6229451]
[27]
Bommareddy, P.K.; Shettigar, M.; Kaufman, H.L. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol., 2018, 18(8), 498-513.
[http://dx.doi.org/10.1038/s41577-018-0014-6] [PMID: 29743717]
[28]
Hemminki, O.; dos Santos, J.M.; Hemminki, A. Oncolytic viruses for cancer immunotherapy. J. Hematol. Oncol., 2020, 13(1), 84.
[http://dx.doi.org/10.1186/s13045-020-00922-1] [PMID: 32600470]
[29]
DeWeese, T.L.; van der Poel, H.; Li, S.; Mikhak, B.; Drew, R.; Goemann, M.; Hamper, U.; DeJong, R.; Detorie, N.; Rodriguez, R.; Haulk, T.; DeMarzo, A.M.; Piantadosi, S.; Yu, D.C.; Chen, Y.; Henderson, D.R.; Carducci, M.A.; Nelson, W.G.; Simons, J.W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res., 2001, 61(20), 7464-7472.
[PMID: 11606381]
[30]
Leber, MF; Bossow, S; Leonard, VH; Zaoui, K; Grossardt, C; Frenzke, M MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol. Ther., 2011, 19(6), 1097-1106.
[http://dx.doi.org/10.1038/mt.2011.55]
[31]
Grossardt, C.; Engeland, C.E.; Bossow, S.; Halama, N.; Zaoui, K.; Leber, M.F.; Springfeld, C.; Jaeger, D.; von Kalle, C.; Ungerechts, G. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum. Gene Ther., 2013, 24(7), 644-654.
[http://dx.doi.org/10.1089/hum.2012.205] [PMID: 23642239]
[32]
Choi, I-K.; Lee, J-S.; Zhang, S-N.; Park, J.; Lee, K-M.; Sonn, C.H.; Yun, C-O. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα. Gene Ther., 2011, 18(9), 898-909.
[http://dx.doi.org/10.1038/gt.2011.37] [PMID: 21451575]
[33]
van Rikxoort, M.; Michaelis, M.; Wolschek, M.; Muster, T.; Egorov, A.; Seipelt, J.; Doerr, H.W.; Cinatl, J., Jr. Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame. PLoS One, 2012, 7(5), e36506.
[http://dx.doi.org/10.1371/journal.pone.0036506] [PMID: 22563505]
[34]
Cerullo, V.; Pesonen, S.; Diaconu, I.; Escutenaire, S.; Arstila, P.T.; Ugolini, M.; Nokisalmi, P.; Raki, M.; Laasonen, L.; Särkioja, M.; Rajecki, M.; Kangasniemi, L.; Guse, K.; Helminen, A.; Ahtiainen, L.; Ristimäki, A.; Räisänen-Sokolowski, A.; Haavisto, E.; Oksanen, M.; Karli, E.; Karioja-Kallio, A.; Holm, S.L.; Kouri, M.; Joensuu, T.; Kanerva, A.; Hemminki, A. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res., 2010, 70(11), 4297-4309.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-3567] [PMID: 20484030]
[35]
Autio, K.; Knuuttila, A.; Kipar, A.; Pesonen, S.; Guse, K.; Parviainen, S.; Rajamäki, M.; Laitinen-Vapaavuori, O.; Vähä-Koskela, M.; Kanerva, A.; Hemminki, A. Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding cd40 ligand in laboratory beagles. Mol. Ther. Oncolytics, 2014, 1, 14002.
[http://dx.doi.org/10.1038/mto.2014.2] [PMID: 27119092]
[36]
Huang, JH; Zhang, SN; Choi, KJ; Choi, I.K; Kim, JH; Lee, MG Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol ther., 2010, 18(2), 264-274.
[http://dx.doi.org/10.1038/mt.2009.205] [PMID: 19738604]
[37]
Eriksson, E.; Milenova, I.; Wenthe, J.; Ståhle, M.; Leja-Jarblad, J.; Ullenhag, G.; Dimberg, A.; Moreno, R.; Alemany, R.; Loskog, A. Shaping the tumor stroma and sparking immune activation by cd40 and 4-1bb signaling induced by an armed oncolytic virus. Clin. Cancer Res., 2017, 23(19), 5846-5857.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-0285] [PMID: 28536305]
[38]
Rosewell Shaw, A.; Suzuki, M. Recent advances in oncolytic adenovirus therapies for cancer. Curr. Opin. Virol., 2016, 21, 9-15.
[http://dx.doi.org/10.1016/j.coviro.2016.06.009] [PMID: 27379906]
[39]
Mok, W.; Boucher, Y.; Jain, R.K. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res., 2007, 67(22), 10664-10668.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-3107] [PMID: 18006807]
[40]
Rodríguez-García, A.; Giménez-Alejandre, M.; Rojas, J.J.; Moreno, R.; Bazan-Peregrino, M.; Cascalló, M.; Alemany, R. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin. Cancer Res., 2015, 21(6), 1406-1418.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-2213] [PMID: 25391696]
[41]
Pascual-Pasto, G.; Bazan-Peregrino, M.; Olaciregui, N.G.; Restrepo-Perdomo, C.A.; Mato-Berciano, A.; Ottaviani, D.; Weber, K.; Correa, G.; Paco, S.; Vila-Ubach, M.; Cuadrado-Vilanova, M.; Castillo-Ecija, H.; Botteri, G.; Garcia-Gerique, L.; Moreno-Gilabert, H.; Gimenez-Alejandre, M.; Alonso-Lopez, P.; Farrera-Sal, M.; Torres-Manjon, S.; Ramos-Lozano, D.; Moreno, R.; Aerts, I.; Doz, F.; Cassoux, N.; Chapeaublanc, E.; Torrebadell, M.; Roldan, M.; König, A.; Suñol, M.; Claverol, J.; Lavarino, C. Carmen de, T.; Fu, L.; Radvanyi, F.; Munier, F.L.; Catalá-Mora, J.; Mora, J.; Alemany, R.; Cascalló, M.; Chantada, G.L.; Carcaboso, A.M. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Sci. Transl. Med., 2019, 11(476), eaat9321.
[http://dx.doi.org/10.1126/scitranslmed.aat9321] [PMID: 30674657]
[42]
Frentzen, A.; Yu, Y.A.; Chen, N.; Zhang, Q.; Weibel, S.; Raab, V.; Szalay, A.A. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc. Natl. Acad. Sci. USA, 2009, 106(31), 12915-12920.
[http://dx.doi.org/10.1073/pnas.0900660106] [PMID: 19617539]
[43]
Hutzen, B.; Bid, H.K.; Houghton, P.J.; Pierson, C.R.; Powell, K.; Bratasz, A.; Raffel, C.; Studebaker, A.W. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin. BMC Cancer, 2014, 14(1), 206.
[http://dx.doi.org/10.1186/1471-2407-14-206] [PMID: 24646176]
[44]
Tsuji, T.; Nakamori, M.; Iwahashi, M.; Nakamura, M.; Ojima, T.; Iida, T.; Katsuda, M.; Hayata, K.; Ino, Y.; Todo, T.; Yamaue, H. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. Int. J. Cancer, 2013, 132(2), 485-494.
[http://dx.doi.org/10.1002/ijc.27681] [PMID: 22729516]
[45]
Goodwin, J.M.; Schmitt, A.D.; McGinn, C.M.; Fuchs, B.C.; Kuruppu, D.; Tanabe, K.K.; Lanuti, M. Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model. Cancer Invest., 2012, 30(3), 243-250.
[http://dx.doi.org/10.3109/07357907.2012.654870] [PMID: 22360364]
[46]
Torre, L.A.; Trabert, B.; DeSantis, C.E.; Miller, K.D.; Samimi, G.; Runowicz, C.D.; Gaudet, M.M.; Jemal, A.; Siegel, R.L. Ovarian cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(4), 284-296.
[http://dx.doi.org/10.3322/caac.21456] [PMID: 29809280]
[47]
Yang, C.; Xia, B.R.; Zhang, Z.C.; Zhang, Y.J.; Lou, G.; Jin, W.L. Immunotherapy for ovarian cancer: Adjuvant, combination, and neoadjuvant. Front. Immunol., 2020, 11, 577869.
[http://dx.doi.org/10.3389/fimmu.2020.577869] [PMID: 33123161]
[48]
Brightwell, R.M.; Grzankowski, K.S.; Lele, S.; Eng, K.; Arshad, M.; Chen, H.; Odunsi, K. The CD47 “don’t eat me signal” is highly expressed in human ovarian cancer. Gynecol. Oncol., 2016, 143(2), 393-397.
[http://dx.doi.org/10.1016/j.ygyno.2016.08.325] [PMID: 27569584]
[49]
Raki, M.; Särkioja, M.; Desmond, R.A.; Chen, D.T.; Bützow, R.; Hemminki, A.; Kanerva, A. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol. Oncol., 2008, 108(1), 166-172.
[http://dx.doi.org/10.1016/j.ygyno.2007.09.013] [PMID: 17950450]
[50]
Ingemarsdotter, C.K.; Baird, S.K.; Connell, C.M.; Öberg, D.; Halldén, G.; McNeish, I.A. Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene, 2010, 29(45), 6051-6063.
[http://dx.doi.org/10.1038/onc.2010.335] [PMID: 20729921]
[51]
Nawa, A.; Nozawa, N.; Goshima, F.; Nagasaka, T.; Kikkawa, F.; Niwa, Y.; Nakanishi, T.; Kuzuya, K.; Nishiyama, Y. Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model. Gynecol. Oncol., 2003, 91(1), 81-88.
[http://dx.doi.org/10.1016/s0090-8258(03)00417-7] [PMID: 14529666]
[52]
Goshima, F.; Esaki, S.; Luo, C.; Kamakura, M.; Kimura, H.; Nishiyama, Y. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer. Int. J. Cancer, 2014, 134(12), 2865-2877.
[http://dx.doi.org/10.1002/ijc.28631] [PMID: 24265099]
[53]
Fu, X.; Tao, L.; Zhang, X. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther., 2007, 14(5), 480-487.
[http://dx.doi.org/10.1038/sj.cgt.7701033] [PMID: 17290283]
[54]
Coukos, G.; Makrigiannakis, A.; Kang, E.H.; Rubin, S.C.; Albelda, S.M.; Molnar-Kimber, K.L. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin. Cancer Res., 2000, 6(8), 3342-3353.
[PMID: 10955822]
[55]
Coukos, G.; Makrigiannakis, A.; Montas, S.; Kaiser, L.R.; Toyozumi, T.; Benjamin, I.; Albelda, S.M.; Rubin, S.C.; Molnar-Kimber, K.L. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther., 2000, 7(2), 275-283.
[http://dx.doi.org/10.1038/sj.cgt.7700130] [PMID: 10770637]
[56]
Blank, S.V.; Rubin, S.C.; Coukos, G.; Amin, K.M.; Albelda, S.M.; Molnar-Kimber, K.L. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum. Gene Ther., 2002, 13(5), 627-639.
[http://dx.doi.org/10.1089/10430340252837224] [PMID: 11916486]
[57]
Abdullahi, S.; Jäkel, M.; Behrend, S.J.; Steiger, K.; Topping, G.; Krabbe, T.; Colombo, A.; Sandig, V.; Schiergens, T.S.; Thasler, W.E.; Werner, J.; Lichtenthaler, S.F.; Schmid, R.M.; Ebert, O.; Altomonte, J. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma. J. Virol., 2018, 92(23)
[http://dx.doi.org/10.1128/jvi.01386-18] [PMID: 30232179]
[58]
Hammad, M.; Cornejo, Y.; Flores, L.; Hyde, C.; Ngai, H.W.; Li, M.; Dellinger, T.H.; Lu, J.; Chen, N.G.; Mooney, R.; Aboody, K.S.; Fong, Y. Novel Chimeric Poxvirus CF17 Improves Survival in a Murine Model of Intraperitoneal Ovarian Cancer Metastasis. Mol. Ther. Oncolytics, 2020, 19, 278-282.
[http://dx.doi.org/10.1016/j.omto.2020.10.002] [PMID: 33251335]
[59]
Whilding, L.M.; Archibald, K.M.; Kulbe, H.; Balkwill, F.R.; Öberg, D.; McNeish, I.A. Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol. Ther., 2013, 21(11), 2074-2086.
[http://dx.doi.org/10.1038/mt.2013.195] [PMID: 23985697]
[60]
Mori, K.M.; Giuliano, P.D.; Lopez, K.L.; King, M.M.; Bohart, R.; Goldstein, B.H. Pronounced clinical response following the oncolytic vaccinia virus GL-ONC1 and chemotherapy in a heavily pretreated ovarian cancer patient. Anticancer Drugs, 2019, 30(10), 1064-1066.
[http://dx.doi.org/10.1097/cad.0000000000000836] [PMID: 31567308]
[61]
van den Pol, A.N.; Zhang, X.; Lima, E.; Pitruzzello, M.; Albayrak, N.; Alvero, A.; Davis, J.N.; Mor, G. Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response. Virology, 2021, 555, 44-55.
[http://dx.doi.org/10.1016/j.virol.2020.10.009] [PMID: 33453650]
[62]
Gebremeskel, S.; Nelson, A.; Walker, B.; Oliphant, T.; Lobert, L.; Mahoney, D.; Johnston, B. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. J. Immunother. Cancer, 2021, 9(3)
[http://dx.doi.org/10.1136/jitc-2020-002096] [PMID: 33722907]
[63]
Jennings, V.A.; Ilett, E.J.; Scott, K.J.; West, E.J.; Vile, R.; Pandha, H.; Harrington, K.; Young, A.; Hall, G.D.; Coffey, M.; Selby, P.; Errington-Mais, F.; Melcher, A.A. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Int. J. Cancer, 2014, 134(5), 1091-1101.
[http://dx.doi.org/10.1002/ijc.28450] [PMID: 23982804]
[64]
Unno, Y.; Shino, Y.; Kondo, F.; Igarashi, N.; Wang, G.; Shimura, R.; Yamaguchi, T.; Asano, T.; Saisho, H.; Sekiya, S.; Shirasawa, H. Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain. Clin. Cancer Res., 2005, 11(12), 4553-4560.
[http://dx.doi.org/10.1158/1078-0432.Ccr-04-2610] [PMID: 15958641]
[65]
Keshavarz, M.; Nejad, A.S.M.; Esghaei, M.; Bokharaei-Salim, F.; Dianat-Moghadam, H.; Keyvani, H.; Ghaemi, A. Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis. Saudi J Biol Sci, 2020, 27(1), 47-52.
[http://dx.doi.org/10.1016/j.sjbs.2019.04.015] [PMID: 31889816]
[66]
Kagabu, M.; Yoshino, N.; Saito, T.; Miura, Y.; Takeshita, R.; Murakami, K.; Kawamura, H.; Baba, T.; Sugiyama, T. The efficacy of a third-generation oncolytic herpes simplex viral therapy for an HPV-related uterine cervical cancer model. Int J Clin Oncol, 2021, 26(3), 591-597.
[http://dx.doi.org/10.1007/s10147-020-01823-6] [PMID: 33146805]
[67]
Nakamori, M.; Fu, X.; Meng, F.; Jin, A.; Tao, L.; Bast, R.C., Jr; Zhang, X. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin. Cancer Res., 2003, 9(7), 2727-2733.
[PMID: 12855653]
[68]
Thomas, E.D.; Meza-Perez, S.; Bevis, K.S.; Randall, T.D.; Gillespie, G.Y.; Langford, C.; Alvarez, R.D. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice. J. Ovarian Res., 2016, 9(1), 70.
[http://dx.doi.org/10.1186/s13048-016-0282-3] [PMID: 27784340]
[69]
Ni, J.; Feng, H.; Xu, X.; Liu, T.; Ye, T.; Chen, K.; Li, G. Oncolytic Vaccinia Virus Harboring Aphrocallistes vastus Lectin Inhibits the Growth of Cervical Cancer Cells Hela S3. Mar. Drugs, 2021, 19(10)
[http://dx.doi.org/10.3390/md19100532] [PMID: 34677432]
[70]
Kuryk, L.; Møller, A.W. Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor. J. Med. Virol., 2020, 92(8), 1309-1315.
[http://dx.doi.org/10.1002/jmv.25677] [PMID: 31944306]
[71]
Heise, C.; Ganly, I.; Kim, Y.T.; Sampson-Johannes, A.; Brown, R.; Kirn, D. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther., 2000, 7(22), 1925-1929.
[http://dx.doi.org/10.1038/sj.gt.3301319] [PMID: 11127580]
[72]
Huang, Y.; Lv, S.Q.; Liu, P.Y.; Ye, Z.L.; Yang, H.; Li, L.F.; Zhu, H.L.; Wang, Y.; Cui, L.Z.; Jiang, D.Q.; Hao, F.Y.; Xu, H.M.; Jin, H.J.; Qian, Q.J. A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer. Mol. Oncol., 2020, 14(3), 657-668.
[http://dx.doi.org/10.1002/1878-0261.12628] [PMID: 31899582]
[73]
Bauerschmitz, G.J.; Lam, J.T.; Kanerva, A.; Suzuki, K.; Nettelbeck, D.M.; Dmitriev, I.; Krasnykh, V.; Mikheeva, G.V.; Barnes, M.N.; Alvarez, R.D.; Dall, P.; Alemany, R.; Curiel, D.T.; Hemminki, A. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res., 2002, 62(5), 1266-1270.
[PMID: 11888888]
[74]
Bauerschmitz, G.J.; Kanerva, A.; Wang, M.; Herrmann, I.; Shaw, D.R.; Strong, T.V.; Desmond, R.; Rein, D.T.; Dall, P.; Curiel, D.T.; Hemminki, A. Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int. J. Cancer, 2004, 111(2), 303-309.
[http://dx.doi.org/10.1002/ijc.20217] [PMID: 15197787]
[75]
Santos, J.M.; Heiniö, C.; Cervera-Carrascon, V.; Quixabeira, D.C.A.; Siurala, M.; Havunen, R.; Butzow, R.; Zafar, S.; de Gruijl, T.; Lassus, H.; Kanerva, A.; Hemminki, A. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. J. Immunother. Cancer, 2020, 8(1)
[http://dx.doi.org/10.1136/jitc-2019-000188] [PMID: 31940588]
[76]
Uusi-Kerttula, H.; Davies, J.A.; Thompson, J.M.; Wongthida, P.; Evgin, L.; Shim, K.G.; Bradshaw, A.; Baker, A.T.; Rizkallah, P.J.; Jones, R.; Hanna, L.; Hudson, E.; Vile, R.G.; Chester, J.D.; Parker, A.L. Ad5(NULL)-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies. Clin. Cancer Res., 2018, 24(17), 4215-4224.
[http://dx.doi.org/10.1158/1078-0432.Ccr-18-1089] [PMID: 29798908]
[77]
Li, F.; Yuan, Y.; Dai, Y.; Cheng, T.; Cao, H.; Yan, D.; Li, Y.; Sun, Q.; Huang, X.; Gao, Q. M11: A Tropism-Modified Oncolytic Adenovirus Arming with a Tumor-Homing Peptide for Advanced Ovarian Cancer Therapies. Hum. Gene Ther., 2022, 33(5-6), 262-274.
[http://dx.doi.org/10.1089/hum.2021.247] [PMID: 35018835]
[78]
Han, Z.; Hong, Z.; Gao, Q.; Chen, C.; Hao, Z.; Ji, T.; Hu, W.; Yan, Y.; Feng, J.; Liao, S.; Wu, P.; Wang, D.; Wang, S.; Zhou, J.; Ma, D. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer. Hum. Gene Ther., 2012, 23(1), 32-45.
[http://dx.doi.org/10.1089/hum.2011.101] [PMID: 21875334]
[79]
Wang, H.; Song, X.; Zhang, H.; Zhang, J.; Shen, X.; Zhou, Y.; Fan, X.; Dai, L.; Qian, G.; Hoffman, A.R.; Hu, J.F.; Ge, S. Potentiation of tumor radiotherapy by a radiation-inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts. Int. J. Cancer, 2012, 130(2), 443-453.
[http://dx.doi.org/10.1002/ijc.26013] [PMID: 21351100]
[80]
Han, X.; Wang, S.; Zhou, W.; Li, Y.; Lei, W.; Lv, W. Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer. Mol. Med. Rep., 2015, 12(1), 435-441.
[http://dx.doi.org/10.3892/mmr.2015.3355] [PMID: 25684632]
[81]
Heideman, D.A.; Steenbergen, R.D.; van der Torre, J.; Scheffner, M.; Alemany, R.; Gerritsen, W.R.; Meijer, C.J.; Snijders, P.J.; van Beusechem, V.W. Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer. Mol. Ther., 2005, 12(6), 1083-1090.
[http://dx.doi.org/10.1016/j.ymthe.2005.06.443] [PMID: 16085463]
[82]
Wang, W.; Sima, N.; Kong, D.; Luo, A.; Gao, Q.; Liao, S.; Li, W.; Han, L.; Wang, J.; Wang, S.; Lu, Y.; Wang, D.; Xu, G.; Zhou, J.; Meng, L.; Ma, D. Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo. Cancer Lett., 2010, 291(1), 67-75.
[http://dx.doi.org/10.1016/j.canlet.2009.09.022] [PMID: 19903581]
[83]
Hamada, K.; Shirakawa, T.; Gotoh, A.; Roth, J.A.; Follen, M. Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer. Gynecol. Oncol., 2006, 103(3), 820-830.
[http://dx.doi.org/10.1016/j.ygyno.2006.06.035] [PMID: 16908054]
[84]
Kim, K.H.; Dmitriev, I.; O’Malley, J.P.; Wang, M.; Saddekni, S.; You, Z.; Preuss, M.A.; Harris, R.D.; Aurigemma, R.; Siegal, G.P.; Zinn, K.R.; Curiel, D.T.; Alvarez, R.D. A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin. Cancer Res., 2012, 18(12), 3440-3451.
[http://dx.doi.org/10.1158/1078-0432.Ccr-11-2852] [PMID: 22510347]
[85]
Chalikonda, S.; Kivlen, M.H.; O’Malley, M.E.; Eric Dong, X.D.; McCart, J.A.; Gorry, M.C.; Yin, X.Y.; Brown, C.K.; Zeh, H.J. 3rd; Guo, Z.S.; Bartlett, D.L. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther., 2008, 15(2), 115-125.
[http://dx.doi.org/10.1038/sj.cgt.7701110] [PMID: 18084242]
[86]
Liu, Y.P.; Wang, J.; Avanzato, V.A.; Bakkum-Gamez, J.N.; Russell, S.J.; Bell, J.C.; Peng, K.W. Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol. Oncol., 2014, 132(3), 722-729.
[http://dx.doi.org/10.1016/j.ygyno.2014.01.009] [PMID: 24434058]
[87]
Galanis, E.; Atherton, P.J.; Maurer, M.J.; Knutson, K.L.; Dowdy, S.C.; Cliby, W.A.; Haluska, P., Jr; Long, H.J.; Oberg, A.; Aderca, I.; Block, M.S.; Bakkum-Gamez, J.; Federspiel, M.J.; Russell, S.J.; Kalli, K.R.; Keeney, G.; Peng, K.W.; Hartmann, L.C. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res., 2015, 75(1), 22-30.
[http://dx.doi.org/10.1158/0008-5472.Can-14-2533] [PMID: 25398436]
[88]
Liu, Y.P.; Steele, M.B.; Suksanpaisan, L.; Federspiel, M.J.; Russell, S.J.; Peng, K.W.; Bakkum-Gamez, J.N. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. Gynecol. Oncol., 2014, 132(1), 194-202.
[http://dx.doi.org/10.1016/j.ygyno.2013.11.010] [PMID: 24246772]
[89]
Hartkopf, A.D.; Bossow, S.; Lampe, J.; Zimmermann, M.; Taran, F.A.; Wallwiener, D.; Fehm, T.; Bitzer, M.; Lauer, U.M. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase. Gynecol. Oncol., 2013, 130(2), 362-368.
[http://dx.doi.org/10.1016/j.ygyno.2013.05.004] [PMID: 23676551]
[90]
Galanis, E.; Hartmann, L.C.; Cliby, W.A.; Long, H.J.; Peethambaram, P.P.; Barrette, B.A.; Kaur, J.S.; Haluska, P.J., Jr; Aderca, I.; Zollman, P.J.; Sloan, J.A.; Keeney, G.; Atherton, P.J.; Podratz, K.C.; Dowdy, S.C.; Stanhope, C.R.; Wilson, T.O.; Federspiel, M.J.; Peng, K.W.; Russell, S.J. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res., 2010, 70(3), 875-882.
[http://dx.doi.org/10.1158/0008-5472.Can-09-2762] [PMID: 20103634]
[91]
Matuszewska, K.; Santry, L.A.; van Vloten, J.P.; AuYeung, A.W.K.; Major, P.P.; Lawler, J.; Wootton, S.K.; Bridle, B.W.; Petrik, J. Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer. Clin. Cancer Res., 2019, 25(5), 1624-1638.
[http://dx.doi.org/10.1158/1078-0432.Ccr-18-0220] [PMID: 30206160]
[92]
Yang, S.W.; Cody, J.J.; Rivera, A.A.; Waehler, R.; Wang, M.; Kimball, K.J.; Alvarez, R.A.; Siegal, G.P.; Douglas, J.T.; Ponnazhagan, S. Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy. Clin. Cancer Res., 2011, 17(3), 538-549.
[http://dx.doi.org/10.1158/1078-0432.Ccr-10-1628] [PMID: 21115652]
[93]
Rein, D.T.; Volkmer, A.; Beyer, I.M.; Curiel, D.T.; Janni, W.; Dragoi, A.; Hess, A.P.; Maass, N.; Baldus, S.E.; Bauerschmitz, G.; Breidenbach, M. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus. Gynecol. Oncol., 2011, 123(1), 138-146.
[http://dx.doi.org/10.1016/j.ygyno.2011.06.007] [PMID: 21741695]
[94]
Yue, E.; Yang, G.; Yao, Y.; Wang, G.; Mohanty, A.; Fan, F.; Zhao, L.; Zhang, Y.; Mirzapoiazova, T.; Walser, T.C.; Rodriguez-Rodriguez, L.; Fong, Y.; Salgia, R.; Wang, E.W. Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment. Cancers (Basel), 2021, 13(17)
[http://dx.doi.org/10.3390/cancers13174265] [PMID: 34503075]
[95]
Cui, Y.; Li, Y.; Li, S.; Li, W.; Zhu, Y.; Wang, J.; Liu, X.; Yue, Y.; Jin, N.; Li, X. Anti-tumor effect of a dual cancer-specific recombinant adenovirus on ovarian cancer cells. Exp. Cell Res., 2020, 396(1), 112185.
[http://dx.doi.org/10.1016/j.yexcr.2020.112185] [PMID: 32828827]
[96]
Hsu, K.F.; Wu, C.L.; Huang, S.C.; Hsieh, J.L.; Huang, Y.S.; Chen, Y.F.; Shen, M.R.; Chung, W.J.; Chou, C.Y.; Shiau, A.L. Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy. Cancer Gene Ther., 2008, 15(8), 526-534.
[http://dx.doi.org/10.1038/cgt.2008.37] [PMID: 18497852]
[97]
Moreno, V.; Barretina-Ginesta, M.P.; García-Donas, J.; Jayson, G.C.; Roxburgh, P.; Vázquez, R.M.; Michael, A.; Antón-Torres, A.; Brown, R.; Krige, D.; Champion, B.; McNeish, I. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. J. Immunother. Cancer, 2021, 9(12)
[http://dx.doi.org/10.1136/jitc-2021-003645] [PMID: 34893524]
[98]
Manyam, M.; Stephens, A.J.; Kennard, J.A.; LeBlanc, J.; Ahmad, S.; Kendrick, J.E.; Holloway, R.W. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer. Gynecol. Oncol., 2021, 163(3), 481-489.
[http://dx.doi.org/10.1016/j.ygyno.2021.10.069] [PMID: 34686353]
[99]
Zappasodi, R.; Merghoub, T.; Wolchok, J.D. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell, 2018, 33(4), 581-598.
[http://dx.doi.org/10.1016/j.ccell.2018.03.005] [PMID: 29634946]
[100]
Chiu, M.; Armstrong, E.J.L.; Jennings, V.; Foo, S.; Crespo-Rodriguez, E.; Bozhanova, G.; Patin, E.C.; McLaughlin, M.; Mansfield, D.; Baker, G.; Grove, L.; Pedersen, M.; Kyula, J.; Roulstone, V.; Wilkins, A.; McDonald, F.; Harrington, K.; Melcher, A. Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert Opin. Biol. Ther., 2020, 20(6), 635-652.
[http://dx.doi.org/10.1080/14712598.2020.1729351] [PMID: 32067509]
[101]
Wong, H.H.; Lemoine, N.R.; Wang, Y. Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses, 2010, 2(1), 78-106.
[http://dx.doi.org/10.3390/v2010078] [PMID: 20543907]
[102]
Ma, D. [The opportunities and challenges of gynecologic cancer in precision medicine] Zhonghua Yi Xue Za Zhi, 2022, 102(26), 1963-1966.
[http://dx.doi.org/10.3760/cma.j.cn112137-20211028-02392] [PMID: 35817720]
[103]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[104]
Arbyn, M.; Weiderpass, E.; Bruni, L.; de Sanjosé, S.; Saraiya, M.; Ferlay, J.; Bray, F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob. Health, 2020, 8(2), e191-e203.
[http://dx.doi.org/10.1016/s2214-109x(19)30482-6] [PMID: 31812369]
[105]
Koh, W.J.; Abu-Rustum, N.R.; Bean, S.; Bradley, K.; Campos, S.M.; Cho, K.R.; Chon, H.S.; Chu, C.; Clark, R.; Cohn, D.; Crispens, M.A.; Damast, S.; Dorigo, O.; Eifel, P.J.; Fisher, C.M.; Frederick, P.; Gaffney, D.K.; Han, E.; Huh, W.K.; Lurain, J.R.; Mariani, A.; Mutch, D.; Nagel, C.; Nekhlyudov, L.; Fader, A.N.; Remmenga, S.W.; Reynolds, R.K.; Tillmanns, T.; Ueda, S.; Wyse, E.; Yashar, C.M.; McMillian, N.R.; Scavone, J.L. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl. Compr. Canc. Netw., 2019, 17(1), 64-84.
[http://dx.doi.org/10.6004/jnccn.2019.0001] [PMID: 30659131]
[106]
Pfaendler, K.S.; Tewari, K.S. Changing paradigms in the systemic treatment of advanced cervical cancer. Am. J. Obstet. Gynecol., 2016, 214(1), 22-30.
[http://dx.doi.org/10.1016/j.ajog.2015.07.022] [PMID: 26212178]
[107]
Goradel, N.H.; Mohajel, N.; Malekshahi, Z.V.; Jahangiri, S.; Najafi, M.; Farhood, B.; Mortezaee, K.; Negahdari, B.; Arashkia, A. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches. J. Cell. Physiol., 2019, 234(6), 8636-8646.
[http://dx.doi.org/10.1002/jcp.27850] [PMID: 30515798]
[108]
Cordeiro, M.N.; De Lima, R.C.P.; Paolini, F.; Melo, A.; Campos, A.P.F.; Venuti, A.; De Freitas, A.C. Current research into novel therapeutic vaccines against cervical cancer. Expert Rev. Anticancer Ther., 2018, 18(4), 365-376.
[http://dx.doi.org/10.1080/14737140.2018.1445527] [PMID: 29475377]
[109]
Morice, P.; Leary, A.; Creutzberg, C.; Abu-Rustum, N.; Darai, E. Endometrial cancer. Lancet, 2016, 387(10023), 1094-1108.
[http://dx.doi.org/10.1016/s0140-6736(15)00130-0] [PMID: 26354523]
[110]
Garcia, A.A.; Blessing, J.A.; Nolte, S.; Mannel, R.S. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol. Oncol., 2008, 111(1), 22-26.
[http://dx.doi.org/10.1016/j.ygyno.2008.06.013] [PMID: 18675446]
[111]
Zhang, L.; Steele, M.B.; Jenks, N.; Grell, J.; Suksanpaisan, L.; Naik, S.; Federspiel, M.J.; Lacy, M.Q.; Russell, S.J.; Peng, K.W. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS Hum. Gene Ther. Clin. Dev., 2016, 27(3), 111-122.
[http://dx.doi.org/10.1089/humc.2016.061] [PMID: 27532609]
[112]
Moerdyk-Schauwecker, M.; Shah, N.R.; Murphy, A.M.; Hastie, E.; Mukherjee, P.; Grdzelishvili, V.Z. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology, 2013, 436(1), 221-234.
[http://dx.doi.org/10.1016/j.virol.2012.11.014] [PMID: 23246628]
[113]
Russell, L.; Peng, K.W.; Russell, S.J.; Diaz, R.M. Oncolytic Viruses: Priming Time for Cancer Immunotherapy. BioDrugs, 2019, 33(5), 485-501.
[http://dx.doi.org/10.1007/s40259-019-00367-0] [PMID: 31321623]
[114]
Moaven, O.; Mangieri, C.W.; Stauffer, J.A.; Anastasiadis, P.Z.; Borad, M.J. Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy. JCO Precis. Oncol., 2021, 5
[http://dx.doi.org/10.1200/po.21.00003] [PMID: 34250395]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy